Mike Gallup, CEO of Norstella, Evaluate’s parent company said: “Key assumptions that have underpinned the pharmaceutical sector for so long – for example, the US market’s supreme profitability and reliance on big M&A to fuel growth – are being tested. “The far-reaching Inflation Reduction Act (IRA), combined with .
Evaluate wins Best Decision Management Solution at 2023 AI Breakthrough Awards Prestigious International Annual Awards Programme Honours Standout AI and Machine Learning Solutions and Companies LONDON AND BOSTON - June 21, 2023 – Evaluate, a Norstella company, today announced that its Evaluate.
New World Preview report finds strong top-line growth as pricing and patent headwinds build
London, UK and Boston, MA – 18 October 2022: The global pharmaceutical industry is set to see sales grow by an annualised 6% between 2022 and 2028, according to the latest World Preview published by Evaluate Ltd.
(0)
Evaluate, a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, is delighted to announce that it has completed the acquisition of Bioscience Advisors Inc. (Biosci), a California-based data company focused on biopharma alliances. The acquisition will significantly expand the richness and quantity of biopharma deal data available to Evaluate clients, furthering Evaluate s mission to provide the most complete and dynamic valuations of pharmaceutical assets.
Founded in 2011, Biosci is best known for their leading BiosciDB database, the most comprehensive reference database on biopharma alliances. BiosciDB provides access to three decades of publicly filed biopharma deals, including 11,000 unredacted contracts. As a result, biopharma dealmakers and their advisors can easily inspect key deal provisions, find relevant deal comparables, compare financial terms and identify best practices in deal drafting.
Evaluate Vantage
Pharma, Biotech & Medtech 2020 in Review report, published today. Companies developing COVID-19 treatments experienced some of the largest gains; the greatest market cap increases by percentage were Novovax (2,702%) and South Korea’s Shin Poong (1,613%).
2020 also saw an unprecedented amount of cash flow into the sector. Drug developers raised a record-breaking $12.7 billion via IPO. This was more than twice the total raised in 2019, and the average amount raised ($167 million) nearly doubled. Private companies also broke records, with an astonishing $20bn invested by venture financers, although the total number of financing rounds was lower than in prior years.
For medical device makers, 2020 delivered split outcomes. The most successful large-cap companies like Teladoc and Novocure saw share prices double, but others like Boston Scientific and Becton Dickinson saw double-digit losses. Privately-held device companies benefitted from an influx of venture capital